Switch to:
Also traded in: Argentina, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.52
NYSE:MRK's Cash to Debt is ranked lower than
67% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NYSE:MRK: 0.52 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:MRK' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.68 Max: 2.45
Current: 0.52
0.32
2.45
Equity to Asset 0.45
NYSE:MRK's Equity to Asset is ranked lower than
74% of the 722 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:MRK: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:MRK' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.44 Max: 0.53
Current: 0.45
0.34
0.53
Interest Coverage 11.47
NYSE:MRK's Interest Coverage is ranked lower than
71% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.15 vs. NYSE:MRK: 11.47 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.14  Med: 9.88 Max: 20.11
Current: 11.47
4.14
20.11
F-Score: 7
Z-Score: 3.34
M-Score: -2.56
WACC vs ROIC
8.19%
11.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 19.60
NYSE:MRK's Operating margin (%) is ranked higher than
80% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.25 vs. NYSE:MRK: 19.60 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:MRK' s Operating margin (%) Range Over the Past 10 Years
Min: 6.43  Med: 16.45 Max: 21.86
Current: 19.6
6.43
21.86
Net-margin (%) 13.76
NYSE:MRK's Net-margin (%) is ranked higher than
76% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. NYSE:MRK: 13.76 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:MRK' s Net-margin (%) Range Over the Past 10 Years
Min: 1.87  Med: 13.3 Max: 47.04
Current: 13.76
1.87
47.04
ROE (%) 12.41
NYSE:MRK's ROE (%) is ranked higher than
69% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.55 vs. NYSE:MRK: 12.41 )
Ranked among companies with meaningful ROE (%) only.
NYSE:MRK' s ROE (%) Range Over the Past 10 Years
Min: 1.51  Med: 14.91 Max: 42.27
Current: 12.41
1.51
42.27
ROA (%) 5.53
NYSE:MRK's ROA (%) is ranked higher than
62% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NYSE:MRK: 5.53 )
Ranked among companies with meaningful ROA (%) only.
NYSE:MRK' s ROA (%) Range Over the Past 10 Years
Min: 0.79  Med: 6.5 Max: 16.34
Current: 5.53
0.79
16.34
ROC (Joel Greenblatt) (%) 55.82
NYSE:MRK's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.88 vs. NYSE:MRK: 55.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:MRK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.9  Med: 42.24 Max: 105.49
Current: 55.82
10.9
105.49
Revenue Growth (3Y)(%) -3.30
NYSE:MRK's Revenue Growth (3Y)(%) is ranked lower than
74% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NYSE:MRK: -3.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:MRK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.5  Med: 2.3 Max: 21.4
Current: -3.3
-16.5
21.4
EBITDA Growth (3Y)(%) -6.40
NYSE:MRK's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. NYSE:MRK: -6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:MRK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.6  Med: 3.9 Max: 44.8
Current: -6.4
-17.6
44.8
EPS Growth (3Y)(%) -7.90
NYSE:MRK's EPS Growth (3Y)(%) is ranked lower than
69% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NYSE:MRK: -7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:MRK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.3  Med: 6.7 Max: 73.8
Current: -7.9
-29.3
73.8
» NYSE:MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MRK Guru Trades in Q4 2015

John Buckingham 24,665 sh (New)
Tom Russo 3,836 sh (New)
Joel Greenblatt 753,471 sh (+12793.07%)
Jim Simons 1,752,234 sh (+19.87%)
Richard Snow 998,514 sh (+16.09%)
Jeff Auxier 153,403 sh (+8.42%)
Charles Brandes 3,012,572 sh (+7.90%)
Barrow, Hanley, Mewhinney & Strauss 26,655,176 sh (+5.86%)
PRIMECAP Management 2,790,000 sh (+5.48%)
Vanguard Health Care Fund 50,476,700 sh (+1.47%)
Ken Fisher 6,822,070 sh (+0.89%)
Mairs and Power 104,637 sh (+0.49%)
Kahn Brothers 1,010,927 sh (+0.47%)
Jeremy Grantham 4,200 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Ruane Cunniff 4,994 sh (unchged)
David Carlson 250,000 sh (unchged)
Prem Watsa Sold Out
Dodge & Cox 24,563,150 sh (-0.09%)
Murray Stahl 43,031 sh (-0.55%)
NWQ Managers 68,615 sh (-1.75%)
Mario Gabelli 139,615 sh (-2.17%)
Paul Tudor Jones 40,561 sh (-9.18%)
First Eagle Investment 7,790 sh (-13.92%)
T Rowe Price Equity Income Fund 5,610,000 sh (-14.63%)
Ray Dalio 156,246 sh (-37.94%)
Pioneer Investments 989,884 sh (-71.12%)
Manning & Napier Advisors, Inc 578,810 sh (-90.63%)
» More
Q1 2016

MRK Guru Trades in Q1 2016

Richard Pzena 921,365 sh (New)
David Dreman 710 sh (New)
John Burbank 1,370,117 sh (New)
Paul Tudor Jones 714,430 sh (+1661.37%)
First Eagle Investment 16,090 sh (+106.55%)
Joel Greenblatt 1,248,557 sh (+65.71%)
Ray Dalio 210,746 sh (+34.88%)
PRIMECAP Management 2,992,800 sh (+7.27%)
Murray Stahl 45,497 sh (+5.73%)
John Buckingham 25,885 sh (+4.95%)
Barrow, Hanley, Mewhinney & Strauss 26,663,511 sh (+0.03%)
Tom Russo 3,836 sh (unchged)
Robert Bruce 259,400 sh (unchged)
David Carlson 250,000 sh (unchged)
NWQ Managers Sold Out
Jeremy Grantham Sold Out
Jeff Auxier 153,303 sh (-0.07%)
Dodge & Cox 24,543,704 sh (-0.08%)
Charles Brandes 3,000,058 sh (-0.42%)
Ken Fisher 6,698,235 sh (-1.82%)
Ruane Cunniff 4,894 sh (-2.00%)
Kahn Brothers 985,419 sh (-2.52%)
Mairs and Power 101,850 sh (-2.66%)
Signature Select Canadian Fund 149,400 sh (-3.24%)
Vanguard Health Care Fund 48,728,100 sh (-3.46%)
Pioneer Investments 925,463 sh (-6.51%)
Richard Snow 911,027 sh (-8.76%)
Manning & Napier Advisors, Inc 501,558 sh (-13.35%)
Mario Gabelli 118,145 sh (-15.38%)
T Rowe Price Equity Income Fund 4,702,900 sh (-16.17%)
Jim Simons 484,334 sh (-72.36%)
» More
Q2 2016

MRK Guru Trades in Q2 2016

Tom Gayner 5,600 sh (New)
Jim Simons 2,926,534 sh (+504.24%)
Richard Pzena 1,415,390 sh (+53.62%)
Ray Dalio 251,546 sh (+19.36%)
Ken Fisher 6,759,345 sh (+0.91%)
Mairs and Power 102,164 sh (+0.31%)
Jeff Auxier 153,303 sh (unchged)
Robert Bruce 259,400 sh (unchged)
David Dreman 710 sh (unchged)
Murray Stahl 45,497 sh (unchged)
David Carlson 250,000 sh (unchged)
Tom Russo Sold Out
John Burbank Sold Out
Barrow, Hanley, Mewhinney & Strauss 26,516,070 sh (-0.55%)
Dodge & Cox 24,372,814 sh (-0.70%)
John Buckingham 25,676 sh (-0.81%)
PRIMECAP Management 2,967,700 sh (-0.84%)
Kahn Brothers 964,925 sh (-2.08%)
Pioneer Investments 901,916 sh (-2.54%)
Charles Brandes 2,891,914 sh (-3.60%)
Mario Gabelli 113,505 sh (-3.93%)
Vanguard Health Care Fund 46,499,820 sh (-4.57%)
Richard Snow 848,738 sh (-6.84%)
Ruane Cunniff 3,981 sh (-18.66%)
Manning & Napier Advisors, Inc 404,399 sh (-19.37%)
T Rowe Price Equity Income Fund 3,500,000 sh (-25.58%)
First Eagle Investment 7,790 sh (-51.58%)
Joel Greenblatt 540,222 sh (-56.73%)
Paul Tudor Jones 3,900 sh (-99.45%)
» More
Q3 2016

MRK Guru Trades in Q3 2016

Jeremy Grantham 7,500 sh (New)
Stanley Druckenmiller 683,800 sh (New)
Steven Cohen 179,800 sh (New)
Tweedy Browne 3,306 sh (New)
Samuel Isaly 247,081 sh (New)
Paul Tudor Jones 612,800 sh (+15612.82%)
David Carlson 275,000 sh (+10.00%)
Ken Fisher 6,817,544 sh (+0.86%)
Tom Gayner 5,600 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
David Dreman 710 sh (unchged)
Murray Stahl 45,497 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Ray Dalio Sold Out
Ruane Cunniff Sold Out
Jeff Auxier 153,153 sh (-0.10%)
PRIMECAP Management 2,964,300 sh (-0.11%)
John Buckingham 25,560 sh (-0.45%)
Richard Pzena 1,408,678 sh (-0.47%)
Kahn Brothers 957,991 sh (-0.72%)
Charles Brandes 2,812,318 sh (-2.75%)
T Rowe Price Equity Income Fund 3,375,000 sh (-3.57%)
Mairs and Power 96,933 sh (-5.12%)
Mario Gabelli 107,405 sh (-5.37%)
Richard Snow 792,347 sh (-6.64%)
Vanguard Health Care Fund 41,516,228 sh (-10.72%)
Manning & Napier Advisors, Inc 335,976 sh (-16.92%)
Dodge & Cox 18,327,311 sh (-24.80%)
Barrow, Hanley, Mewhinney & Strauss 18,581,032 sh (-29.93%)
Pioneer Investments 602,479 sh (-33.20%)
Joel Greenblatt 330,785 sh (-38.77%)
Jim Simons 1,303,400 sh (-55.46%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:NVS, NYSE:PFE, NYSE:SNY, NYSE:ABBV, NYSE:BMY, OTCPK:GLAXF, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH » details
Traded in other countries:MRK.Argentina, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.

Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Company's operations are managed on a products basis and are comprised of four operating segments, the Pharmaceutical, Animal Health, Alliances and Healthcare Services segments. The Pharmaceutical segment is the only reportable segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, administered at physician offices. The Company sells these human health vaccines to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. The Alliances segment includes results from the Company's relationship with AstraZeneca LP until the termination of that relationship on June 30, 2014. The Company's Healthcare Services segment provides services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company's pharmaceutical products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Products within the Company's franchises are - Primary Care and Women's Health include Cardiovascular, Diabetes, and General Medicine and Women's Health; Hospital and Specialty include Hepatitis, HIV, Hospital Acute Care, and Immunology; Oncology includes Keytruda, Emend, Temodar, and Temodal; Diversified Brands includes Respiratory and Others; and Vaccines. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. Principal products in this segment include - Livestock Products; Poultry Products; Companion Animal Products; and Aquaculture Products. The Company's competitors include other research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers and animal health care companies.

Top Ranked Articles about Merck & Co Inc

Merck Reports Triple-Combo Results The therapy achieved high success rates in clinical trials with hepatitis C patients
Merck & Co. Inc. (NYSE:MRK) announced through Business Wire on Nov. 14 that the “results from three phase 2 clinical trials evaluating MK-3682B (MK3682/grazoprevir/ruzasvir1), the company’s investigational all-oral, triple-combination regimen" for the treatment of patients who are chronically infected with the hepatitis C virus, are ready to be presented at The Liver Meeting® 2016 Monday (C-CREST 1 & 2 Parts B and C) and Tuesday (C-SURGE). Read more...
Insiders Are Buying Hertz and Selling Merck Largest insider buys and sales of the week
The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$200,000+” duration to November 2016 and All Insider Sales to “$5,000,000+”. Read more...
Merck: Promising Results From Immunotherapy Based on Keytruda Merck presented the results of two studies on the first-line treatment of advanced lung cancer
Very promising are the results of two studies on the first-line treatment of advanced lung cancer because of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, presented on Oct. 9 at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark.
Read more...
Sanofi Sues Merck Over Patent Infringement Company trying to prevent further competition, reverse declining sales
French pharmaceutical giant Sanofi SA (NYSE:SNY) filed a lawsuit against Merck & Co. (NYSE:MRK) for supposed patent infringements last Friday. Read more...
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth A low-risk dividend for the short to mid term
From the price to sales point of view, Merck (NYSE:MRK) is one of the most expensive healthcare stocks, trading at nearly 4.5 times sales, more than you need to pay for Pfizer (NYSE:PFE) or Novartis (NYSE:NVS). Merck is possibly the only pharma major to see its stock price almost steadily rise in the last five years. It has more than doubled its price during that time, from under $30 in August 2011 to above $60 in August 2016. Read more...
Revenue and Earnings Higher for Merck in the Second Quarter Merck reports good second quarter results
Merck (NYSE:MRK) reported second quarter earnings on Friday, July 29. The Dow Jones Industrial Average component beat earnings estimates for both revenue and earnings per share. Revenue for the quarter was $9.84 billion, beating estimates by $60 million. Earnings per share for the quarter were 93 cents, beating estimates by 0.02 cents. Read more...
Merck CEO Sells 60,000 Company Shares Company's vice president sells 75,000 shares in 2 transactions
Kenneth Frazier (Insider Trades), CEO, president and chairman of Merck & Co. Inc. (MRK), sold 60,000 company shares at a per share price of $58.00 on July 5. The total transaction was $3.48 million. Read more...
Merck CEO Kenneth Frazier Sells 131,040 Shares Merck has 2 products recently approved by FDA
Kenneth Frazier (Insider Trades), CEO, president and chairman of Merck & Co. Inc. (MRK), sold 131,040 shares of the company on April 14. The average price per share was $56.11 for a total transaction cost of $7,352,654. Merck is a pharmaceuticals company that provides prescription medicines, vaccines, biologic therapies and animal health products worldwide. The company has a market cap of $155.49 billion and a P/S ratio of 3.97. Read more...
5 Guru Picks in Volatile Biotech Industry Johnson & Johnson and Merck each have the backing of more than 25 gurus
Biotech and pharmaceutical stocks made some of the biggest headlines this year, as 2015 saw massive waves of M&A activity, including the Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) merger, the second-largest deal of all time valued at $160 billion. Other companies found themselves in the spotlight for less than desirable reasons, such as Valeant Pharmaceuticals (NYSE:VRX), whose stock has tanked in the past several months. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.07
MRK's P/E(ttm) is ranked lower than
56% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.49 vs. MRK: 31.07 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.33  Med: 20.82 Max: 138.33
Current: 31.07
6.33
138.33
Forward P/E 15.77
MRK's Forward P/E is ranked lower than
52% of the 63 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.41 vs. MRK: 15.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.07
MRK's PE(NRI) is ranked lower than
57% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.46 vs. MRK: 31.07 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s PE(NRI) Range Over the Past 10 Years
Min: 6.33  Med: 20.82 Max: 138.33
Current: 31.07
6.33
138.33
Price/Owner Earnings (ttm) 22.82
MRK's Price/Owner Earnings (ttm) is ranked higher than
65% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.53 vs. MRK: 22.82 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MRK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.1  Med: 15.94 Max: 48.31
Current: 22.82
6.1
48.31
P/B 3.82
MRK's P/B is ranked lower than
64% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. MRK: 3.82 )
Ranked among companies with meaningful P/B only.
MRK' s P/B Range Over the Past 10 Years
Min: 1.72  Med: 3.23 Max: 7.25
Current: 3.82
1.72
7.25
P/S 4.26
MRK's P/S is ranked lower than
64% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. MRK: 4.26 )
Ranked among companies with meaningful P/S only.
MRK' s P/S Range Over the Past 10 Years
Min: 2.02  Med: 3.32 Max: 5.48
Current: 4.26
2.02
5.48
PFCF 18.28
MRK's PFCF is ranked higher than
56% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. MRK: 18.28 )
Ranked among companies with meaningful PFCF only.
MRK' s PFCF Range Over the Past 10 Years
Min: 7.87  Med: 16.2 Max: 89.14
Current: 18.28
7.87
89.14
POCF 15.68
MRK's POCF is ranked higher than
53% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.41 vs. MRK: 15.68 )
Ranked among companies with meaningful POCF only.
MRK' s POCF Range Over the Past 10 Years
Min: 6.67  Med: 13.48 Max: 35.85
Current: 15.68
6.67
35.85
EV-to-EBIT 23.88
MRK's EV-to-EBIT is ranked lower than
57% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.07 vs. MRK: 23.88 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 15 Max: 52.6
Current: 23.88
4.9
52.6
EV-to-EBITDA 13.44
MRK's EV-to-EBITDA is ranked higher than
64% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.70 vs. MRK: 13.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 9.35 Max: 23.2
Current: 13.44
4.2
23.2
PEG 3.40
MRK's PEG is ranked lower than
65% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. MRK: 3.40 )
Ranked among companies with meaningful PEG only.
MRK' s PEG Range Over the Past 10 Years
Min: 0.55  Med: 2.51 Max: 18.63
Current: 3.4
0.55
18.63
Shiller P/E 26.38
MRK's Shiller P/E is ranked higher than
73% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.94 vs. MRK: 26.38 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s Shiller P/E Range Over the Past 10 Years
Min: 8.3  Med: 16.66 Max: 28.13
Current: 26.38
8.3
28.13
Current Ratio 1.89
MRK's Current Ratio is ranked lower than
59% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. MRK: 1.89 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.6 Max: 3.7
Current: 1.89
1.07
3.7
Quick Ratio 1.56
MRK's Quick Ratio is ranked lower than
56% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. MRK: 1.56 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.28 Max: 3.44
Current: 1.56
0.8
3.44
Days Inventory 142.77
MRK's Days Inventory is ranked lower than
62% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.28 vs. MRK: 142.77 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 104.23  Med: 136.75 Max: 209.2
Current: 142.77
104.23
209.2
Days Sales Outstanding 67.35
MRK's Days Sales Outstanding is ranked higher than
58% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.78 vs. MRK: 67.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.45  Med: 58.77 Max: 87.87
Current: 67.35
53.45
87.87
Days Payable 62.85
MRK's Days Payable is ranked lower than
57% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.88 vs. MRK: 62.85 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 30.2  Med: 44.78 Max: 90.53
Current: 62.85
30.2
90.53

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.03
MRK's Dividend Yield is ranked higher than
76% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. MRK: 3.03 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s Dividend Yield Range Over the Past 10 Years
Min: 2.51  Med: 3.74 Max: 6.68
Current: 3.03
2.51
6.68
Dividend Payout 0.94
MRK's Dividend Payout is ranked lower than
80% of the 386 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. MRK: 0.94 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s Dividend Payout Range Over the Past 10 Years
Min: 0.15  Med: 0.54 Max: 4.22
Current: 0.94
0.15
4.22
Dividend Growth (3y) 2.30
MRK's Dividend Growth (3y) is ranked lower than
63% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.00 vs. MRK: 2.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MRK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 2.8 Max: 14.8
Current: 2.3
0
14.8
Forward Dividend Yield 3.09
MRK's Forward Dividend Yield is ranked higher than
75% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. MRK: 3.09 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.63
MRK's Yield on cost (5-Year) is ranked higher than
71% of the 791 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. MRK: 3.63 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.01  Med: 4.49 Max: 8.01
Current: 3.63
3.01
8.01
3-Year Average Share Buyback Ratio 2.80
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 435 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. MRK: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.1 Max: 2.8
Current: 2.8
-13
2.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.47
MRK's Price/Tangible Book is ranked lower than
98% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. MRK: 33.47 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.19  Med: 12.79 Max: 3112.5
Current: 33.47
3.19
3112.5
Price/Projected FCF 1.39
MRK's Price/Projected FCF is ranked higher than
74% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. MRK: 1.39 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.24 Max: 3.04
Current: 1.39
0.75
3.04
Price/Median PS Value 1.28
MRK's Price/Median PS Value is ranked lower than
60% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. MRK: 1.28 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.19 Max: 1.97
Current: 1.28
0.64
1.97
Price/Graham Number 6.78
MRK's Price/Graham Number is ranked lower than
93% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. MRK: 6.78 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.09  Med: 3.93 Max: 31.92
Current: 6.78
1.09
31.92
Earnings Yield (Greenblatt) (%) 4.24
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. MRK: 4.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 6.7 Max: 20.5
Current: 4.24
1.9
20.5
Forward Rate of Return (Yacktman) (%) 8.33
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.15 vs. MRK: 8.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.8  Med: 6.7 Max: 21.9
Current: 8.33
-6.8
21.9

More Statistics

Revenue (TTM) (Mil) $39,907
EPS (TTM) $ 1.95
Beta0.89
Short Percentage of Float0.80%
52-Week Range $47.97 - 65.46
Shares Outstanding (Mil)2,757.14

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 39,931 40,229 41,856 41,889
EPS ($) 3.71 3.90 4.28 4.24
EPS w/o NRI ($) 3.71 3.90 4.28 4.24
EPS Growth Rate
(3Y to 5Y Estimate)
4.48%
Dividends Per Share ($) 1.83 1.85 1.86
» More Articles for MRK

Headlines

Articles On GuruFocus.com
US Market Indexes Lower With Gains for the Week Nov 18 2016 
Stan Druckenmiller Axes Halliburton, Gains 5 New Positions Nov 17 2016 
Stocks Lower on Wednesday After Election Gains Nov 16 2016 
Merck Reports Triple-Combo Results Nov 14 2016 
Insiders Are Buying Hertz and Selling Merck Nov 11 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 
Merck Announces 3rd-Quarter Results Oct 25 2016 
Buy Merck on Drops to $60 Oct 16 2016 
US Market Indexes Lower on Tuesday Oct 11 2016 
Oil Prices Help Stock Valuations on Monday Oct 10 2016 

More From Other Websites
KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical... Dec 05 2016
Nasdaq Leads As Techs Rally; Nike Runs Ahead On Dow, But Merck Weighs Dec 05 2016
At What Cost? Weighing A Cure For Cancer Against Its Pricetag Dec 05 2016
Inside Merck’s Profitability after 3Q16 Dec 05 2016
10:43 am Merck announces updated Keytruda findings in patients with relapsed or refractory primary... Dec 05 2016
Updated KEYTRUDA® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary... Dec 05 2016
Kite Pharma Begins Filing for KTE-C19, Presents Data at ASH Dec 05 2016
Merck CEO Ken Frazier Is A Quote Machine Dec 04 2016
Tech Data’s board gets more diverse with addition of former Merck executive Dec 02 2016
Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda Dec 02 2016
AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy Dec 02 2016
Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta? Dec 02 2016
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma Dec 02 2016
Merck KGaA (MKGAF) Expands Distribution Deal with Roche Dec 02 2016
Keytruda Is Merck’s Immuno-Oncology Business Dec 02 2016
Label Expansion May Boost Venclexta’s Growth Prospects Dec 02 2016
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda Dec 02 2016
Merck wins UK okay for Keytruda in lung cancer after price cut Dec 01 2016
Pharma execs weigh in on possible changes under Trump Dec 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)